1. Connecting lean and green with sustainability towards a conceptual model. (1st November 2021) Authors: Teixeira, P.; Sá, J.C.; Silva, F.J.G.; Ferreira, L.P.; Santos, G.; Fontoura, P. Journal: Journal of cleaner production Issue: Volume 322(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFNβ-1a–controlled OPERA I and OPERA II studies. Issue 10 (October 2017) Authors: Ziemssen, T.; Bar-Or, A.; Arnold, D.L.; Comi, G.; Hartung, H.P.; Hauser, S.L.; Lublin, F.; Selmaj, K.; Traboulsee, A.; Chin, P.; Fontoura, P.; Garren, H.; Masterman, D.; Kappos, L. Journal: Clinical neurophysiology Issue: Volume 128:Issue 10(2017:Oct.) Page Start: e326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P33 Thirty-six-month amyloid PET results show continued reduction in amyloid burden with gantenerumab. Issue 4 (April 2020) Authors: Klein, G.; Duning, T.; Delmar, P.; Kerchner, G.A.; Hofmann, C.; Abi-Saab, D.; Ristic, S.; Davis, A.; Voyle, N.; Baudler, M.; Fontoura, P.; Doody, R. Journal: Clinical neurophysiology Issue: Volume 131:Issue 4(2020:Apr.) Page Start: e195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P37 Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer's disease. Issue 8 (August 2019) Authors: Boada, M.; Ristic, S.; Pross, N.; Abi-Saab, D.; Bullain, S.; Andjelkovic, M.; Peters, O.; Delmar, P.; Hofmann, C.; Searle, A.; Baudler, M.; Fontoura, P.; Doody, R. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗